KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other financing activities (2016 - 2023)

Travere Therapeutics (TVTX) has disclosed Other financing activities for 10 consecutive years, with -$259000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Other financing activities fell 102.2% year-over-year to -$259000.0, compared with a TTM value of -$259000.0 through Sep 2024, down 102.44%, and an annual FY2023 reading of -$1.4 million, down 113.99% over the prior year.
  • Other financing activities was -$259000.0 for Q4 2023 at Travere Therapeutics, roughly flat from -$260000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $11.8 million in Q4 2022 and bottomed at -$11.8 million in Q3 2022.
  • Average Other financing activities over 4 years is $316800.0, with a median of -$259000.0 recorded in 2023.
  • The sharpest move saw Other financing activities soared 292.61% in 2022, then crashed 165.74% in 2023.
  • Year by year, Other financing activities stood at $772000.0 in 2019, then tumbled by 890.67% to -$6.1 million in 2021, then skyrocketed by 292.61% to $11.8 million in 2022, then plummeted by 102.2% to -$259000.0 in 2023.
  • Business Quant data shows Other financing activities for TVTX at -$259000.0 in Q4 2023, -$260000.0 in Q3 2023, and -$259000.0 in Q2 2023.